18 July 2018 - - Lawrence Mermel has accepted a position on the Cranford, New Jersey-based specialty pharmaceutical company Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) scientific advisory board, the company said.
Mermel is Professor of Medicine at the Warren Alpert Medical School of Brown University. Mermel joins Isaam Raad, the chair of MD Anderson Cancer Center's Department of Infectious Diseases (also chairman of the Citius Scientific advisory board), and Mark Rupp, Professor and Chief of the Division of Infectious Diseases at the University of Nebraska Medical Center.
The advisory board will be counseling the company on its development programs, particularly the anti-infective portfolio which includes the company's lead technology, Mino-Lok.
Citius' Mino-Lok product is designed to salvage infected central venous catheters (CVCs) that cause catheter related bloodstream infections (CRBSIs). This is a recognized unmet medical need, as there have been no large scale studies to provide robust evidence on the effectiveness of antibiotic lock therapies.
The company's Mino-Lok product contains a proprietary combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter.
Citius is dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care, and unique prescription products that use innovative, patented or proprietary formulations of previously-approved active pharmaceutical ingredients.